2023 World Conference on Lung Cancer (Posters)-P1.27. Immunotherapy versus Chemotherapy in the Management of Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials

P1.27. Immunotherapy versus Chemotherapy in the Management of Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials - PDF(Slides)

Back to course

Pdf Summary

A meta-analysis was conducted to compare the effectiveness of immune checkpoint inhibitors (ICIs) versus chemotherapy (CMT) alone in the neoadjuvant or adjuvant treatment of resectable non-small-cell lung cancer (NSCLC). Four studies were included in the analysis, and a total of 9,375 articles were identified from the search strategy. <br /><br />The results showed that neoadjuvant CMT with ICI significantly improved overall survival (OS) and disease-free survival (DFS) compared to CMT alone. The pooled hazard ratio (HR) for OS was 0.53 (95% CI: 0.36-0.78) and for DFS was 0.60 (95% CI: 0.44-0.80).<br /><br />For adjuvant CMT with ICI, the OS benefit was not statistically significant (pooled HR: 0.94; 95% CI: 0.78-1.12), but there was a significant improvement in DFS (pooled HR: 0.77; 95% CI: 0.67-0.89). The improvement in DFS was particularly notable in patients with positive PD-L1 status (pooled HR: 0.64; 95% CI: 0.51-0.81) and non-squamous histology (pooled HR: 0.68; 95% CI: 0.58-0.81). However, the addition of ICI to CMT did not significantly improve DFS in PD-L1 negative tumors and tumors with squamous histology. Additionally, there was no improvement in DFS in the presence of EGFR mutation.<br /><br />The findings suggest that neoadjuvant and adjuvant ICI therapy can improve OS and DFS in patients with early-stage, resectable NSCLC, particularly in those with positive PD-L1 status and non-squamous histology. Further trials are needed to better understand the role of ICIs in this clinical scenario.

Asset Subtitle

Ben Ponvilawan

Meta Tag

Speaker Ben Ponvilawan

Topic Early-Stage NSCLC: Innovation & New Technology

Keywords

immune checkpoint inhibitors

chemotherapy

neoadjuvant treatment

adjuvant treatment

resectable non-small-cell lung cancer

overall survival

disease-free survival

pooled hazard ratio

PD-L1 status

non-squamous histology